Skip to main content
. Author manuscript; available in PMC: 2012 Feb 11.
Published in final edited form as: Vaccine. 2010 Dec 21;29(8):1710–1720. doi: 10.1016/j.vaccine.2010.12.020

Fig. 3.

Fig. 3

Immunoblotting analysis of NAP antigen expression in cells infected with the NAP-encoding MV vectors. Chimeric NAP expression was detected in MV-lambda-NAP infected Vero cells by immunoblot using a human lambda immunoglobulin chain specific antibody (A). Serum-free supernatant from MV-lambda (MV-λ) infected Vero cells was used as a positive control. There was no lambda protein detection in uninfected control cells (Vero-co), MV-GFP infected cells (MV-GFP) and the recombinant 6H-NAP and pET28 control extracts (pET-co). The samples were run in duplicates. The arrows indicate position and MW (in kDa) of the marker proteins. KAS-6/1 MM cells were infected with MV-lambda-NAP and the secretion of lambda light immunoglobulin chain or chimeric NAP in the culture supernatant was demonstrated by anti-lambda (a-λ) specific immunoblot (B). Anti-kappa (a-κ) light chain reaction (C) shows the equal presence of kappa light chain of MM IgG in the samples (lane 1 – MV-lambda infected cells; lane 2 – MV-lambda-NAP infected cells; and lane 3 – uninfected KAS-6/1 cells). NAP expression was confirmed by MAb 16F4 immunoblot analysis for MV-lambda-NAP (MV-λ-NAP) but not for MV-NAP (D). Samples were run in duplicate lanes and MV-GFP infected Vero cells were used as control.